| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Dept of Clinical and Biological Sciences, Respiratory Disease Division, University of Turin, Turin, Italy
CORRESPONDENCE: V. De Rose, Clinica di Malattie dell'Apparato Respiratorio, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Osp. S.Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano, Torino, Italy. Fax: 39 119038639. E-mail: virginia.derose@unito.it
Keywords: airway inflammation, cystic fibrosis, inflammatory markers
Received: March 22, 2001
Accepted May 8, 2001
Abstract
Airway inflammation is now recognized as a major factor in the pathogenesis of lung disease in cystic fibrosis (CF). Its most characteristic feature is a marked and persistent influx into the airways of neutrophils, which damage the lung by releasing noxious mediators, such as reactive oxygen species and proteolytic enzymes.
Recent studies suggest that inflammation occurs very early and may even happen in the absence of infection. Furthermore, links between CF transmembrane conductance regulator dysfunction and both infection and inflammation are postulated; dysregulation of cytokine production and abnormal epithelial host defences have been regarded as causes of sustained inflammation.
Bronchoalveolar lavage and the evaluation of neutrophils and inflammatory mediators provide the most accurate picture of airway inflammation. Routine bronchoscopy with bronchoalveolar lavage, however, is unpleasant for the patient and usually is of no immediate benefit to the management of individual cases.
Therefore, surrogate markers collected by noninvasive procedures would be of great assistance in the follow-up of cystic fibrosis patients. Several markers have been evaluated in the sputum, serum and urine of cystic fibrosis patients and related to the degree of airway inflammation. Long-term studies are needed to confirm their potential clinical utility and specificity, and to determine which can be used clinically to monitor disease outcome and efficacy of treatment.
This article has been cited by other articles:
|
|
 |
|
  E. Caraher, J. Collins, G. Herbert, P. G. Murphy, C. G. Gallagher, M. J. Crowe, M. Callaghan, and S. McClean Evaluation of in vitro virulence characteristics of the genus Pandoraea in lung epithelial cells J. Med. Microbiol., January 1, 2008; 57(1): 15 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bergeron, M. K. Tulic, and Q. Hamid Tools used to measure airway remodelling in research Eur. Respir. J., March 1, 2007; 29(3): 596 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xu, D. Zhang, H. Zhang, P. J. Wolters, N. P. Killeen, B. M. Sullivan, R. M. Locksley, C. A. Lowell, and G. H. Caughey Neutrophil histamine contributes to inflammation in mycoplasma pneumonia J. Exp. Med., December 25, 2006; 203(13): 2907 - 2917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Attucci, A. Gauthier, B. Korkmaz, P. Delepine, M. F.-D. Martino, F. Saudubray, P. Diot, and F. Gauthier EPI-hNE4, a Proteolysis-Resistant Inhibitor of Human Neutrophil Elastase and Potential Anti-Inflammatory Drug for Treating Cystic Fibrosis J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 803 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Chen, T. W. Ferkol, M. A. Mintun, J. E. Pittman, D. B. Rosenbluth, and D. P. Schuster Quantifying Pulmonary Inflammation in Cystic Fibrosis with Positron Emission Tomography Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1363 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bergeron and L.-P. Boulet Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest, April 1, 2006; 129(4): 1068 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tabary, H. Corvol, E. Boncoeur, K. Chadelat, C. Fitting, J. M. Cavaillon, A. Clement, and J. Jacquot Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L588 - L596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Elkins, M. Robinson, B. R. Rose, C. Harbour, C. P. Moriarty, G. B. Marks, E. G. Belousova, W. Xuan, P. T.P. Bye, and the National Hypertonic Saline in Cystic Fibrosis A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis N. Engl. J. Med., January 19, 2006; 354(3): 229 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Sloane, R. A. Lindner, S. S. Prasad, L. T. Sebastian, S. K. Pedersen, M. Robinson, P. T. Bye, D. W. Nielson, and J. L. Harry Proteomic Analysis of Sputum from Adults and Children with Cystic Fibrosis and from Control Subjects Am. J. Respir. Crit. Care Med., December 1, 2005; 172(11): 1416 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Kettle, T. Chan, I. Osberg, R. Senthilmohan, A. L. P. Chapman, T. J. Mocatta, and J. S. Wagener Myeloperoxidase and Protein Oxidation in the Airways of Young Children with Cystic Fibrosis Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1317 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Paul, E. Rietschel, M. Ballmann, M. Griese, D. Worlitzsch, J. Shute, C. Chen, T. Schink, G. Doring, S. van Koningsbruggen, et al. Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 15, 2004; 169(6): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gilljam, Y. Moltyaner, G. P. Downey, R. Devlin, P. Durie, A. M. Cantin, J. Zielenski, and D. E. Tullis Airway Inflammation and Infection in Congenital Bilateral Absence of the Vas Deferens Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 174 - 179. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
